These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 22923753

  • 1. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
    Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO, Duncan B, Goel N, Davies OR, Dougados M.
    Rheumatology (Oxford); 2012 Dec; 51(12):2204-14. PubMed ID: 22923753
    [Abstract] [Full Text] [Related]

  • 2. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M.
    Arthritis Res Ther; 2015 Nov 15; 17():325. PubMed ID: 26568428
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 15; 24(5):715-24. PubMed ID: 24313916
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Jul 15; 24(4):552-60. PubMed ID: 24981319
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 15; 24(5):734-43. PubMed ID: 24593170
    [Abstract] [Full Text] [Related]

  • 6. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H.
    Ann Rheum Dis; 2015 May 15; 74(5):843-50. PubMed ID: 24431394
    [Abstract] [Full Text] [Related]

  • 7. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
    Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, Staelens F, Koetse W, Bertin P.
    Arthritis Care Res (Hoboken); 2015 Feb 15; 67(2):151-60. PubMed ID: 25302624
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 15; 24(5):725-33. PubMed ID: 24372225
    [Abstract] [Full Text] [Related]

  • 9. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
    Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, Mease P, Landewé R, Fleischmann R, Luijtens K, van der Heijde D.
    Rheumatology (Oxford); 2012 Sep 15; 51(9):1628-38. PubMed ID: 22596211
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
    Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D.
    Ann Rheum Dis; 2009 Jun 15; 68(6):797-804. PubMed ID: 19015207
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
    Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.
    Ann Rheum Dis; 2009 Jun 15; 68(6):805-11. PubMed ID: 19015206
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D.
    Ann Rheum Dis; 2014 Dec 15; 73(12):2094-100. PubMed ID: 23918037
    [Abstract] [Full Text] [Related]

  • 13. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
    Østergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, Rell-Bakalarska M, Staelens F, Haake R, Sundman-Engberg B, Bliddal H.
    Ann Rheum Dis; 2015 Jun 15; 74(6):1156-63. PubMed ID: 25512675
    [Abstract] [Full Text] [Related]

  • 14. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.
    Ann Rheum Dis; 2017 Jan 15; 76(1):96-104. PubMed ID: 27165179
    [Abstract] [Full Text] [Related]

  • 15. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
    Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB.
    Ann Rheum Dis; 2014 Dec 15; 73(12):2174-7. PubMed ID: 24972708
    [Abstract] [Full Text] [Related]

  • 16. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
    Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D.
    Ann Rheum Dis; 2014 Jan 15; 73(1):48-55. PubMed ID: 23942868
    [Abstract] [Full Text] [Related]

  • 17. Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.
    Kang YM, Park YE, Park W, Choe JY, Cho CS, Shim SC, Bae SC, Suh CH, Cha HS, Koh EM, Song YW, Yoo B, Lee SS, Park MC, Lee SH, Arendt C, Koetse W, Lee SK.
    Korean J Intern Med; 2018 Nov 15; 33(6):1224-1233. PubMed ID: 29294598
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.
    Bi L, Li Y, He L, Xu H, Jiang Z, Wang Y, Li X, Wei W, Gu J, Wang G, Zhang Z, Zhou B, Liu Y, Wu Z, Liu H, He D, Lv Z, Li Z, Zuo X, Dong L, Wu H, Zhang H, Chen H, Bao C, Zhang Z, Zhang M, Song H, Zheng Y, Jiang L, Liu X, Boehnlein M, Dunkel J, Shao J, Harris K, Li Z.
    Clin Exp Rheumatol; 2019 Nov 15; 37(2):227-234. PubMed ID: 30183595
    [Abstract] [Full Text] [Related]

  • 19. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.
    Arthritis Res Ther; 2009 Nov 15; 11(6):R170. PubMed ID: 19909548
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L, Lapadula G, Mathieu A.
    BioDrugs; 2014 Apr 15; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.